Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LPTX

Leap Therapeutics Inc

Dec 10 • 04:00PM ET

3.16

Dollar change -0.04
Percentage change -1.25	%

Healthcare • Biotechnology • USA • NASD

Peers: AFMD XNCR MTEM KZR ADAP PRQR NKTR RIGL BLRX CYCC

| Held by: VTI PINK VXF IWC DFAC AVSC DFAT DFAS DFSU DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.93	Insider Own	25.48%	Shs Outstand	38.26M	Perf Week	13.26%
Market Cap	121.08M	Forward P/E	-	EPS next Y	-1.28	Insider Trans	0.00%	Shs Float	28.55M	Perf Month	-2.47%
Income	-64.59M	PEG	-	EPS next Q	-0.40	Inst Own	31.82%	Short Float	4.99%	Perf Quarter	14.08%
Sales	0.00M	P/S	-	EPS this Y	53.42%	Inst Trans	-0.19%	Short Ratio	4.35	Perf Half Y	40.44%
Book/sh	1.28	P/B	2.47	EPS next Y	31.07%	ROA	-87.23%	Short Interest	1.42M	Perf Year	16.18%
Cash/sh	1.64	P/C	1.93	EPS next 5Y	-2.49%	ROE	-106.79%	52W Range	1.68 - 5.00	Perf YTD	-23.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	28.36%	ROI	-131.94%	52W High	-36.80%	Beta	0.15
Dividend TTM	-	Quick Ratio	3.97	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	88.10%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	3.97	EPS Y/Y TTM	66.29%	Oper. Margin	-	RSI (14)	54.72	Volatility	12.20% 9.96%
Employees	54	Debt/Eq	0.01	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.40	Target Price	10.70
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	13.08%	Payout	-	Rel Volume	0.65	Prev Close	3.20
Sales Surprise	-	EPS Surprise	10.93%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	327.34K	Price	3.16
SMA20	9.86%	SMA50	6.38%	SMA200	19.58%	Trades		Volume	211,713	Change	-1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$8
Oct-04-21	Initiated	Mizuho	Buy	$6
Jun-04-21	Resumed	Robert W. Baird	Outperform	$5
Jun-29-20	Initiated	Piper Sandler	Overweight	$6
Feb-11-20	Initiated	Robert W. Baird	Outperform	$6
Nov-15-19	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-13-19	Resumed	Raymond James	Outperform
Mar-07-17	Initiated	Ladenburg Thalmann	Buy	$18

Nov-26-24 07:00AM	Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference (PR Newswire) +5.16%
Nov-13-24 07:00AM	Leap Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire) -7.69%
Sep-30-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Aug-12-24 07:00AM	Leap Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
May-13-24 08:31AM	Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress (GuruFocus.com)
07:00AM	Loading…
07:00AM	Leap Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-29-24 04:01AM	Pipeline Moves: Investigator-led trial of Lillys merestinib in solid tumours terminated (Clinical Trials Arena) -5.54%
Apr-11-24 08:30AM	Leap Therapeutics Announces $40 Million Private Placement (PR Newswire)
Mar-20-24 09:35AM	Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks (Zacks) +15.91%
Mar-18-24 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Jan-16-24 05:05PM	Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-03-24 07:00AM	Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients (PR Newswire) +12.67%
Dec-11-23 04:05PM	Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +11.28%
Nov-21-23 07:00AM	Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +17.87%
07:00AM	Loading…
Nov-13-23 07:00AM	Leap Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-03-23 09:55AM	These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird (TipRanks) +26.92%
Sep-05-23 07:00AM	Leap Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-14-23 07:00AM	Leap Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Jul-12-23 07:00AM	Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients (PR Newswire) +6.19%
Jun-20-23 12:30PM	Leap Therapeutics Announces Reverse Stock Split (PR Newswire) -23.22%
Jun-04-23 07:11AM	10 Hot Penny Stocks To Buy (Insider Monkey)
May-25-23 05:10PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) -9.82%
May-15-23 07:00AM	Leap Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-26-23 04:05PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) +6.37%
Apr-12-23 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire) +17.67%
Apr-04-23 11:10AM	Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Mar-24-23 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire)
12:26PM	Loading…
Mar-17-23 12:26PM	BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate (Benzinga) -16.85%
Mar-16-23 04:05PM	Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 (PR Newswire) +6.05%
Jan-17-23 05:13PM	Leap Therapeutics to acquire Pennsylvania biotech in all-stock deal (American City Business Journals) -14.66%
09:24AM	Leap Therapeutics Shares Fall After Flame Biosciences Acquisition (Benzinga)
08:00AM	Leap Therapeutics Acquires Flame Biosciences (PR Newswire)
Jan-11-23 07:00AM	Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference (PR Newswire)
Nov-21-22 07:00AM	Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-16-22 05:20AM	Leap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021) (Simply Wall St.) -5.12%
Nov-14-22 07:00AM	Leap Therapeutics Reports Third Quarter 2022 Financial Results (PR Newswire) +12.62%
Nov-07-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Oct-26-22 08:19AM	Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-17-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Oct-12-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer (PR Newswire)
Oct-05-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Sep-27-22 08:15AM	Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures (GlobeNewswire)
Sep-07-22 07:00AM	Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference (PR Newswire) +8.02%
Sep-06-22 07:00AM	Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors (PR Newswire) +8.72%
Sep-04-22 06:05PM	Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress (PR Newswire)
Aug-12-22 07:00AM	Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute (PR Newswire)
07:00AM	Leap Therapeutics Reports Second Quarter 2022 Financial Results (PR Newswire)
Jul-21-22 07:47AM	Do Institutions Own Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares? (Simply Wall St.)
Jul-14-22 11:37AM	Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal (Zacks)
11:34AM	Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome (Zacks)
Jul-12-22 11:20AM	Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA (Zacks) -8.80%
11:13AM	Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint (Zacks)
07:00AM	Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer (PR Newswire)
Jul-11-22 11:58AM	Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion (Zacks) -6.72%
06:19AM	Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech (Zacks)
Jul-08-22 11:48AM	Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug (Zacks)
11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why (Zacks)
Jul-07-22 11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
Jul-04-22 11:49AM	Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU (Zacks)
Jun-29-22 12:44PM	Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why (Zacks)
12:34PM	Graybug (GRAY) to Review Strategic Alternatives, Stock Up (Zacks)
Jun-28-22 11:52AM	Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD (Zacks) -6.82%
Jun-27-22 07:00AM	Leap Therapeutics to Host Virtual R&D Day on July 12, 2022 (PR Newswire) +9.09%
Jun-17-22 11:16AM	Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry (Zacks)
Jun-13-22 12:01PM	Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development (Zacks) -6.54%
Jun-10-22 10:51AM	Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study (Zacks)
Jun-09-22 10:48AM	Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED (Zacks) -6.67%
Jun-08-22 10:14AM	Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease (Zacks) +10.09%
Jun-07-22 11:30AM	Praxis (PRAX) Tanks on Negative Data From Depression Study (Zacks)
11:23AM	Global Blood's (GBT) Candidates for SCD Get Two FDA Tags (Zacks)
Jun-06-22 10:13AM	GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix (Zacks) -6.84%
09:48AM	Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study (Zacks)
Jun-03-22 10:51AM	Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails (Zacks) +6.36%
10:49AM	Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug (Zacks)
Jun-02-22 12:09PM	Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy (Zacks)
11:24AM	Sanofi (SNY) Gets Breakthrough Therapy Tag for Hemophilia A Drug (Zacks)
May-31-22 11:26AM	GSK to Boost Vaccine Portfolio With Affinivax Acquisition (Zacks)
May-26-22 05:00PM	Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting (PR Newswire) -7.50%
11:18AM	Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe (Zacks)
May-25-22 12:07PM	INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study (Zacks) +6.25%
12:05PM	SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal (Zacks)
May-24-22 10:58AM	Seagen (SGEN) Posts Positive Data from New Study on Tukysa (Zacks)
May-23-22 11:46AM	AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate (Zacks)
11:33AM	Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata (Zacks)
May-19-22 06:15AM	We're Keeping An Eye On Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Rate (Simply Wall St.)
May-13-22 07:00AM	Leap Therapeutics Reports First Quarter 2022 Financial Results (PR Newswire) +34.58%
Apr-09-22 08:57AM	Shareholders in Leap Therapeutics (NASDAQ:LPTX) are in the red if they invested five years ago (Simply Wall St.)
Mar-11-22 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Mar-02-22 07:00AM	Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference (PR Newswire)
Mar-01-22 09:45AM	Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-25-22 08:25AM	Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-15-22 10:14AM	10 Cheap Pharmaceutical Stocks For 2022 (Insider Monkey) +7.14%
Feb-08-22 07:56AM	How Many Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares Do Institutions Own? (Simply Wall St.)
Feb-03-22 05:38PM	Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ... (GuruFocus.com)
Jan-31-22 07:00AM	Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients (PR Newswire) +13.45%
Jan-24-22 07:00AM	Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference (PR Newswire)
Jan-21-22 05:38PM	Community Trust & Investment Co Buys Cheniere Energy Inc, Salesforce. ... (GuruFocus.com) -11.72%

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LPTX

Leap Therapeutics Inc

Upgrade your FINVIZ experience